HCR 1004 is a procedural resolution approving a consent decree resolving a class-action lawsuit against Oklahoma's mental health system. It formally authorizes the Oklahoma Legislature to adopt the court-approved settlement between the Department of Mental Health and Substance Abuse Services, the Oklahoma Forensic Center, and a group of individuals alleging inadequate competency restoration treatment for people found incompetent to stand trial. The decree resolves claims about delays in providing required treatment to ensure court competency, avoiding further litigation costs. This resolution does not create new policy but legally ratifies an existing court agreement.
SB 176 requires health insurance plans to cover certain prescription drugs that were previously not included in standard coverage. It directly affects health insurance providers and policyholders by mandating this specific coverage for eligible medications. The key provision is a new requirement for all health benefit plans to include these designated prescriptions without prior authorization or excessive cost-sharing. The law became effective on May 29, 2025, after the Governor did not sign it.
HB 2947 adds a new provider code in Oklahoma Medicaid for master's and doctoral-level behavioral health clinical interns. These interns - graduate students in nationally accredited programs - can provide services under the direct supervision of licensed behavioral health providers (like LPCs or LCSWs) while following all Medicaid documentation and training requirements. The bill directly affects interns seeking practical experience and licensed supervisors who will oversee their Medicaid-covered services. It expands Medicaid access to behavioral health care by formalizing intern participation in the state's Medicaid plan.
HB 2087 modifies Oklahoma's income tax credit for donations to qualified research institutes. It adjusts annual funding caps: for biomedical research institutes, the limit drops from $2 million to $1.5 million per year starting in 2026, while cancer research institute credits are capped at $500,000 annually. The credit percentage for each donation type is recalculated yearly based on prior-year claims, using specific formulas to stay within these new limits. Taxpayers donating to qualifying nonprofit biomedical or cancer research institutes (defined by NIH funding requirements) can claim the credit, with individual limits of $1,000-$25,000 depending on filing status or business type.
HB 1115 requires Oklahoma's Medicaid program to increase payment rates for mental health services provided to children 19 years of age or younger by 30%. This change directly affects mental health providers who serve Medicaid-eligible children under 19 by raising the reimbursement they receive for these services. The bill mandates a specific 30% rate increase for covered mental health services, without altering eligibility criteria. The policy becomes effective November 1, 2025.
SB 203 requires Oklahoma's Medicaid program to reimburse hospitals 100% of the statewide average nursing facility per diem rate for Medicaid patients who no longer need acute hospital care but require nursing facility-level care upon discharge. This applies specifically when patients cannot be transferred to a nursing facility due to bed shortages or because a court-appointed guardian is pending. The Oklahoma Health Care Authority must seek federal approval to implement this reimbursement, and the bill takes effect July 1, 2025. It directly affects Medicaid-enrolled patients needing nursing care transitions and the hospitals treating them.
The provided context does not include the bill text or specific provisions of SB 1047. Without details on which health care services require reimbursement, the reimbursement mechanisms, or the affected entities (e.g., insurers, providers, patients), a factual summary cannot be created. The bill's title mentions "reimbursement for certain health care services" but lacks concrete policy details in the available information. For an accurate summary, the full bill text or a detailed legislative summary would be required.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
SB 1344 creates Oklahoma's Insulin Access and Affordability Program, administered by the State Department of Health, to increase access to affordable insulin for residents. The bill requires the Department to provide financial support to a nonprofit pharmaceutical manufacturer developing fast-acting biosimilar insulin, contingent on the manufacturer matching funds and agreeing to produce insulin at low cost without rebates (except as required by law). The agreement includes annual reporting on development progress and repayment terms if the insulin isn't produced and distributed as promised. This program directly affects Oklahoma residents needing insulin, public and private payors, and the specified nonprofit manufacturer.
SB 1134 allocates $100,000 from Oklahoma's General Revenue Fund to the Oklahoma Health Care Authority for the 2026 fiscal year. The bill directly provides funding for the Authority to carry out its legal duties. It declares an emergency to allow immediate implementation upon passage. This is a procedural appropriations measure with no policy changes beyond the specified funding amount.
